Navigation Links
Parker Waichman Alonso LLP and Affiliated Lawfirms Have Filed a Class Action Lawsuit in the United States District Court for the Eastern District of New York Against Merck & Co., Inc. and Schering-Plough Corporation
Date:1/18/2008

Great Neck, N.Y., Jan. 18 /PRNewswire/ -- On January 17, 2008, the law firms of Parker Waichman Alonso LLP, Becnel Law Firm, LLC, Douglas & London P.C., Levin Simes Kaiser and Gornick LLP, Bailey Perrin Bailey LLP and Weitz & Luxenberg, P.C., have filed over a Billion ($1,000,000,000) Dollar Class Action lawsuit claiming refunds for purchasers of Vytorin, in Federal District Court, Eastern District of New York, Docket #08-258 before The Honorable Carol Bagley Amon, Judge of the United States Eastern District Court of New York, against Merck & Co., Inc. and Schering-Plough Corporation. The class action seeks, in part, refunds to individuals who were prescribed and purchased the popular cholesterol statin drug, Vytorin(R). Vytorin(R) is a single pill combination of two drugs, Zocor and Zetia, (ezetimibe plus simvastatin).

The lawsuit alleges that Merck & Co., Inc. and Schering-Plough Corporation, the manufacturers of the prescription drug, Vytorin(R), made misrepresentations and withheld significant information in its approval submissions and filings with the Federal Drug Administration. It is also alleged that misrepresentations were made to the general public through marketing efforts as to the effectiveness of the drug. In reality, studies have shown that it is no better than other available drugs on the market in lowering cholesterol.

The above law firms have been contacted and retained by many individuals, including the proposed class representative, who have been prescribed and used Vytorin(R) and who are seeking refunds for their prescriptions.

If you or someone you know was prescribed and purchased, Vytorin(R), please contact our office by visiting our website at http://www.yourlawyer.com. Free case evaluations are also available by calling Parker Waichman Alonso LLP at 1-800-LAW-INFO (1-800-529-4636).


'/>"/>
SOURCE Parker Waichman Alonso LLP
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Keppra XR(TM) Extended-Release Tablets Filed with the FDA
2. Abbott Receives Supplemental FDA Approval for its Best-in-Class in Sensitivity RealTime HIV-1 Viral Load Test
3. Roche Diagnostics HIV Viral Load Test Used in Clinical Trials for Isentress, a New Class of HIV Drug
4. Coley Pharmaceutical Group Diversifies Pipeline with First-in-Class TLR Antagonist for the Treatment of Systemic Lupus Erythematosus
5. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
6. NIST Awards $2 Million to Velcura Therapeutics, Inc. for Innovative Technology R&D - Dual-Action Therapies for Bone Disease
7. Study Results Reveal alli(R) Patient Satisfaction Linked to Weight Loss Achieved; Not Treatment Effects
8. AIDS Action Council Statement on World AIDS Day 2007: Leadership Needed for a National Strategy to Stop the AIDS Epidemic
9. Study Shows That Low-Molecular Weight Heparin (LMWH) was Associated with Reduced Hospital Costs of Venous Thromboembolism (VTE) Treatment Compared with Unfractionated Heparin (UFH)
10. Radiesse Provides Greater Patient Satisfaction Than Either Juvederm or Perlane as Reported in a 205-Patient Clinical Trial Published in the Journal of Dermatologic Surgery
11. Study Linking Increased Risk of Death to Severe Psoriasis a Call to Action
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... , Tenn. and DALLAS , April 19, ... Inc., announced that the first patients in ... EndoStim device in the Lower Esophageal Sphincter Stimulation for ... minimally-invasive implantable device designed to provide long-term reflux control ... GERD affects nearly 65 million people in ...
(Date:4/19/2017)... , April 19, 2017  Novartis today announced ... National Heart, Lung, and Blood Institute (NHLBI) of ... 58% of patients with treatment-na├»ve severe aplastic anemia ... treated with eltrombopag at the initiation of and ... study evaluated three sequential treatment groups, or cohorts. ...
(Date:4/18/2017)... 18, 2017 Research and Markets has announced ... report to their offering. ... global arthroscopy devices market to grow at a CAGR of 6.35% ... Devices Market 2017-2021, has been prepared based on an in-depth market ... landscape and its growth prospects over the coming years. The report ...
Breaking Medicine Technology:
(Date:4/28/2017)... ... ... The Radiology Business Management Association (RBMA) is pleased to announce ... process has been in place since the RBMA was founded in 1968 with all ... Jim Hamilton, MHA, CMM, FRBMA, as president. Dr. Dickerson the chief executive officer for ...
(Date:4/28/2017)... ... April 28, 2017 , ... ... and College of Urgent Care Medicine will host industry leaders for the annual ... will help those in the industry adapt to the issues currently affecting urgent ...
(Date:4/28/2017)... ... , ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh in Abilene, Texas, has ... which He does not. Yisrayl says with so many titles and names for the ... he says with a little Scripture, backed with a lot of research, the truth is ...
(Date:4/28/2017)... (PRWEB) , ... April 28, 2017 , ... ... skincare and advanced nutraceutical supplements, through its Nova Skin Sciences division, recently ... hydrating benefits of a moisturizer with the power of an anti-aging concentrate. ...
(Date:4/28/2017)... ... 2017 , ... Christie Medical Holdings, Inc. , with its market-leading ... Medical Inc. , a leader in infusion therapy and pain management. , Intravenous ... percent of hospital patients receiving a peripheral IV catheter as part of their treatment ...
Breaking Medicine News(10 mins):